Nearly 50 candidates in development.
15 approved medicines developed in-house.
One relentless scientific mission.
Press releases for investors and media
Stay current on Regeneron news and company updates
Press releases
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
Read moreRegeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
Read moreOtarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
Read moreThe Regeneron Scientific Journey
A deep understanding of human biology guides our path to potential medicines
Learn moreVoices of Generalized Myasthenia Gravis
Learn what life is like with generalized myasthenia gravis (gMG)
Learn moreFrom biologics to genetic medicines, our journey turns
cutting-edge science into transformative medicine,
redefining excellence and efficiency in research and development.
We're guided by our philosophy of
doing well by doing good
We’re dedicated to responsible business practices, integrating the highest standards of integrity into every facet of our operations. Our responsibility strategy addresses the issues that matter most to our business and our stakeholders — because we understand that our actions have a profound impact on the world around us.
Careers at Regeneron
Join the brightest, most passionate innovators in science. Find your next opportunity by applying for jobs and internships at Regeneron today.
Our clinical trials
Our journey of discovery continues as we strive to transform the lives of people with serious diseases. Discover more about our clinical trials or locate a relevant trial near you.